ArticleGeroScience2026
Age-adjusted leukocyte telomere length predicts long-term mortality in older patients discharged from acute care hospitals.
Article in GeroScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
Abstract
Leukocyte telomere length (LTL) is a widely studied biomarker of biological aging, reflecting cumulative cellular damage beyond chronological age. However, its prognostic relevance in clinically complex populations such as hospitalized older adults remains uncertain. In this prospective observational study, 872 patients aged ≥ 65 years admitted to acute care wards of IRCCS INRCA within the Report-AGE cohort were included. LTL was measured by quantitative real-time PCR and expressed as age-adjusted residuals derived from an external reference population. The primary outcome was 10-year all-cause mortality. Associations between LTL residuals and mortality were assessed using Cox proportional hazards models, both as continuous variables and using a data-driven cut-point. Multivariable models adjusted for demographic characteristics, comorbidity burden, laboratory parameters, and polypharmacy were used. Effect modification by frailty was evaluated through interaction and stratified analyses. Over a median follow-up of 126.8 months, 713 patients died. Shorter age-adjusted LTL was associated with increased mortality risk in univariable analysis (HR per 1 SD decrease = 1.10, 95% CI 1.02-1.19; p = 0.012). When dichotomized using an optimal cut-point, patients with shorter-than-expected telomeres exhibited significantly higher mortality (adjusted HR = 1.30, 95% CI 1.05-1.60; p = 0.016), regardless of clinical and laboratory covariates. A significant interaction with frailty was observed (p for interaction = 0.031), with the association between LTL and mortality being evident among patients without frailty. Age-adjusted LTL provides independent prognostic information in hospitalized older adults and may reflect biologically meaningful heterogeneity associated with aging, particularly among individuals without frailty.
Indexed as
Identifiers
42350753What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.